Cargando…

Correction to: Prime-boost vaccination strategy enhances immunogenicity compared to single pneumococcal conjugate vaccination in patients receiving conventional DMARDs, to some extent in abatacept but not in rituximab-treated patients

Detalles Bibliográficos
Autores principales:	Nived, Per, Jönsson, Göran, Settergren, Bo, Einarsson, Jon, Olofsson, Tor, Jørgensen, Charlotte Sværke, Skattum, Lillemor, Kapetanovic, Meliha C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318464/ https://www.ncbi.nlm.nih.gov/pubmed/32591025 http://dx.doi.org/10.1186/s13075-020-02256-2

Ejemplares similares

Prime-boost vaccination strategy enhances immunogenicity compared to single pneumococcal conjugate vaccination in patients receiving conventional DMARDs, to some extent in abatacept but not in rituximab-treated patients
por: Nived, Per, et al.
Publicado: (2020)

Methotrexate reduces circulating Th17 cells and impairs plasmablast and memory B cell expansions following pneumococcal conjugate immunization in RA patients
por: Nived, Per, et al.
Publicado: (2021)

Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis
por: Crnkic Kapetanovic, Meliha, et al.
Publicado: (2013)

Antibody response to 13-valent pneumococcal conjugate vaccine is not impaired in patients with rheumatoid arthritis or primary Sjögren’s syndrome without disease modifying treatment
por: Nived, Per, et al.
Publicado: (2018)

Methotrexate Treatment Suppresses Monocytes in Nonresponders to Pneumococcal Conjugate Vaccine in Rheumatoid Arthritis Patients
por: Elmér, Evelina, et al.
Publicado: (2022)

The association between antibody levels before and after 7-valent pneumococcal conjugate vaccine immunization and subsequent pneumococcal infection in chronic arthritis patients
por: Nagel, Johanna, et al.
Publicado: (2015)

Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept
por: Alten, Rieke, et al.
Publicado: (2016)

Rituximab in clinical practice: dosage, drug adherence, Ig levels, infections, and drug antibodies
por: Einarsson, Jon Thorkell, et al.
Publicado: (2017)

The effect of smoking and alcohol consumption on markers of systemic inflammation, immunoglobulin levels and immune response following pneumococcal vaccination in patients with arthritis
por: Roseman, Carmen, et al.
Publicado: (2012)

Persistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different antirheumatic drugs
por: Crnkic Kapetanovic, Meliha, et al.
Publicado: (2013)

Drug adherence to biologic DMARDS with a special emphasis on the benefits of subcutaneous abatacept
por: Malaviya, Anshuman P, et al.
Publicado: (2012)

Common Transcriptomic Effects of Abatacept and Other DMARDs on Rheumatoid Arthritis Synovial Tissue
por: Triaille, Clement, et al.
Publicado: (2021)

Pneumococcal vaccine/rituximab: Acquired humoral deficiency leading to infections and pneumococcal vaccine failure: case report
Publicado: (2021)

Effect of abatacept on the immunogenicity of 23-valent pneumococcal polysaccharide vaccination (PPSV23) in rheumatoid arthritis patients
por: Migita, Kiyoshi, et al.
Publicado: (2015)

Treatment of Rheumatoid Arthritis with Biologic DMARDS (Rituximab and Etanercept)
por: Gashi, Afrim A., et al.
Publicado: (2014)

Primary immunodeficiency in infection-prone children in southern Sweden: occurrence, clinical characteristics and immunological findings
por: Brodszki, Nicholas, et al.
Publicado: (2014)

Abatacept is Efficacious in the Treatment of Older Patients with csDMARD-Refractory Rheumatoid Arthritis: A Prospective, Multicenter, Observational Study
por: Muraoka, Sei, et al.
Publicado: (2021)

Durability of Antibody Response after Primary Pneumococcal Double-Dose Prime-Boost Vaccination in Adult Kidney Transplant Recipients and Candidates: 18-Month Follow-Up in a Non-Blinded, Randomised Clinical Trial
por: Larsen, Lykke, et al.
Publicado: (2022)

Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease among 948,263 individuals ≥ 65 years of age: a Danish cohort study
por: Nielsen, Katrine Finderup, et al.
Publicado: (2022)

Diabetes-Related Complications and Costs in Medicare Beneficiaries with Comorbid Rheumatoid Arthritis and Diabetes Treated with Abatacept Versus Other Targeted DMARDs
por: Patel, Vardhaman, et al.
Publicado: (2022)

The impact of immunomodulating treatment on the immunogenicity of COVID-19 vaccines in patients with immune-mediated inflammatory rheumatic diseases compared to healthy controls. A Swedish nationwide study (COVID19-REUMA)
por: Frodlund, Martina, et al.
Publicado: (2023)

Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects
por: Tay, Lee, et al.
Publicado: (2007)

Pneumococcal conjugate vaccine primes mucosal immune responses to pneumococcal polysaccharide vaccine booster in Papua New Guinean children
por: Orami, Tilda, et al.
Publicado: (2020)

Rituximab and Abatacept Are Effective in Differential Treatment of Interstitial Lymphocytic Lung Disease in Children With Primary Immunodeficiencies
por: Rodina, Yulia, et al.
Publicado: (2021)

Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
por: Malene B, Mikkelsen, et al.
Publicado: (2023)

Streptococcus pneumoniae serotypes/serogroups causing invasive disease in Riyadh, Saudi Arabia: extent of coverage by pneumococcal vaccines
por: Al-Mazrou, Abdulrahman, et al.
Publicado: (2005)

Baseline Anti-Citrullinated Protein Antibody Status and Response to Abatacept or Non-TNFi Biologic/Targeted-Synthetic DMARDs: US Observational Study of Patients with RA
por: Harrold, Leslie R., et al.
Publicado: (2021)

Recent Topics of Pneumococcal Vaccination: Indication of Pneumococcal Vaccine for Individuals at a Risk of Pneumococcal Disease in Adults
por: Asai, Nobuhiro, et al.
Publicado: (2021)

Global Control of Pneumococcal Infections by Pneumococcal Vaccines
por: Oishi, Kazunori, et al.
Publicado: (2014)

Pneumococcal disease and use of pneumococcal vaccines in Taiwan
por: Wei, Sung-Hsi, et al.
Publicado: (2015)

Varicella immunity and vaccine response in children with juvenile idiopathic arthritis treated with DMARD
por: Boldingh, AM, et al.
Publicado: (2011)

Pneumococcal responses are similar in Papua New Guinean children aged 3-5 years vaccinated in infancy with pneumococcal polysaccharide vaccine with or without prior pneumococcal conjugate vaccine, or without pneumococcal vaccination
por: van den Biggelaar, Anita H. J., et al.
Publicado: (2017)

HBV and targeted synthetic (ts)DMARDs: what have we learned from bDMARDs and tsDMARDs?
por: Gremese, Elisa, et al.
Publicado: (2020)

Decrease in Pneumococcal Co-Colonization following Vaccination with the Seven-Valent Pneumococcal Conjugate Vaccine
por: Valente, Carina, et al.
Publicado: (2012)

Effect of Age and Vaccination With a Pneumococcal Conjugate Vaccine on the Density of Pneumococcal Nasopharyngeal Carriage
por: Roca, A., et al.
Publicado: (2012)

Pneumococcal Conjugate Vaccination Followed by Pneumococcal Polysaccharide Vaccination in Lung Transplant Candidates and Recipients
por: Hoffman, Thijs W., et al.
Publicado: (2020)

Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis
por: Huoponen, Saara, et al.
Publicado: (2019)

The accelerated waning of immunity and reduced effect of booster in patients treated with bDMARD and tsDMARD after SARS-CoV-2 mRNA vaccination
por: Tobudic, Selma, et al.
Publicado: (2023)

Comparison of the Impact of Pneumococcal Conjugate Vaccine 10 or Pneumococcal Conjugate Vaccine 13 on Invasive Pneumococcal Disease in Equivalent Populations
por: Naucler, Pontus, et al.
Publicado: (2017)

Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry
por: Choquette, Denis, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_mbc6jo6iu1racrurtq3b2e9bva